Αποτελέσματα Αναζήτησης
Diffuse midline glioma (DMG), formerly called diffuse intrinsic pontine glioma (DIPG), is a high-grade malignant pediatric brain tumor with a near-zero survival rate. To date, only radiation therapy provides marginal survival benefit; however, the median survival time remains less than a year.
- Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle - PMC
Diffuse midline glioma (DMG) is a heterogeneous group of...
- Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle - PMC
3 Νοε 2023 · The standard therapy for newly diagnosed DMG patients is focal conventional fractionated radiation therapy in non-metastatic cases, with a total dose of 54–60 Gy administered over 6 weeks.
As a result, diffuse midline gliomas may sometimes be treated using radiation therapy alone without a biopsy if the risk of biopsy is too high. If the patient has hydrocephalus, a procedure (such as a ventriculoperitoneal shunt) may also be needed to redirect the flow of CSF.
1 Σεπ 2024 · Conventionally fractionated radiation therapy to a total dose of 54-60 Gy in 27-30 fractions and 24 Gy in 12 fractions play a crucial role in the definitive treatment of these tumors in the primary and salvage settings, respectively.
1 Ιουν 2023 · Diffuse midline glioma (DMG) is the leading cause of brain tumor-related deaths in children. DMG typically presents with variable neurologic symptoms between ages 3 and 10. Currently, radiation remains the standard therapy for DMG to halt progression and reduce tumor bulk to minimize symptoms.
21 Ιουν 2024 · Diffuse midline glioma (DMG), H3 K27M-mutant is a type of diffuse high-grade glioma that occurs in the brain midline carrying an extremely poor prognosis under the best efforts of surgery, radiation, and other therapies. For better therapy, we explored the efficacy and toxicity of a novel therapy that combines apatinib and temozolomide in DMG.
Diffuse midline glioma (DMG) is a heterogeneous group of aggressive pediatric brain tumors with a fatal prognosis. The biological hallmark in the major part of the cases is H3K27 alteration. Prognosis remains poor, with median survival ranging from 9 to 12 months from diagnosis.
